Key result
A custom-designed RNA sequencing panel demonstrated 100% sensitivity and 93.33% specificity for detecting gene fusions, successfully identifying fusions in 40% of clinical soft tissue sarcoma samples.
Why the study?
Diagnosis and classification of soft tissue sarcomas remain challenging due to rarity and overlapping morphologic manifestations, while characteristic gene fusions represent useful diagnostic markers.
Does a custom-designed RNA fusions panel improve the detection of gene fusions and classification of soft tissue sarcomas?
Observational (n=145)
Yes
Does a custom-designed RNA fusions panel improve the detection of gene fusions and classification of soft tissue sarcomas?
A custom-designed RNA sequencing panel demonstrated high sensitivity and specificity for detecting gene fusions in soft tissue sarcomas, aiding in precise molecular classification where histopathology is indeterminate.
Supports RNA panel for STS fusion detection; leaves open prospective validation before routine adoption.
The diagnosis and classification of soft tissue sarcomas (STS) remain challenging because of the rarity and overlapping morphologic manifestations of diverse STS subtypes. Characteristic gene fusions are commonly detected in STS and represent useful diagnostic markers. This study established and validated a custom-designed RNA sequencing panel that identified 64 gene fusions in STS. The analytical performance validation yielded excellent accuracy, with 100% (95% CI, 94.40%-100%) sensitivity and 93.33% (95% CI, 68.05%-99.83%) specificity. Clinical performances were further confirmed with 145 clinical formalin-fixed and paraffin-embedded (FFPE) samples from STS patients. Fusions were detected in 40% of samples (58/145). The common fusions SS18-SSX family, EWSR1-related fusions, COL1A1-PDGFB, FOXO1-associated fusions, and FUS-associated fusions were identified in corresponding STS subtypes. The RNA panel detected specific fusions in several cases where no conclusive diagnosis can be made based on the morphology and immunohistochemistry results. Data collected in this study demonstrate that the RNA fusions panel can better classify STS subtypes and serve as a good supplement for histopathology, exhibiting a great potential for the STS precise diagnosis.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2023) conducted an observational in Soft tissue sarcoma (n=145). Custom-designed RNA sequencing panel vs. Fluorescence in situ hybridization (FISH) and reference materials was evaluated on Sensitivity for detecting gene fusions (95% CI 94.40-100). A custom-designed RNA sequencing panel demonstrated 100% sensitivity and 93.33% specificity for detecting gene fusions, successfully identifying fusions in 40% of clinical soft tissue sarcoma samples.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: